Health Care & Life Sciences » Biotechnology | Esperion Therapeutics Inc.

Esperion Therapeutics Inc.

Esperion Therapeutics Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
26.8 M
Public Float
24.26 M
Esperion Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$2.74
Market Cap
$1.27 B
Shares Outstanding
26.92 M
Public Float
24.9 M

Profile

Address
3891 Ranchero Drive
Ann Arbor Michigan 48108
United States
Employees -
Website http://www.esperion.com
Updated 07/08/2019
Esperion Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). It offers Bempedoic acid and Ezetime combination pill as therapies that have been shown to lower elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. The company was founded by Roger S.

Financials

View All

Tim M. Mayleben
President, Chief Executive Officer & Director
Jay P. Shepard
Director